Dr. Mark Bagarazzi
Chief Medical Officer
Dr. Mark Bagarazzi has been the Chief Medical Officer of Inovio Pharmaceuticals since 2010. Prior to Inovio, he was Director of Worldwide Regulatory Affairs at Merck & Co, where he led vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. He was responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. He also successfully led the regulatory process culminating in FDA approval of RotaTeq®, Merck’s vaccine against rotavirus. Prior to joining Merck in 2001, he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia. Previously he was an assistant professor of pediatrics at Drexel College of Medicine and a guest lecturer at Johns Hopkins University.